Track how API export origins are gaining or losing share. India grew 31.7% from 2022 to 2024; minor origins are halving. Quantify your geographic exposure.
India's share of observable API export origin moved from 97.9% in 2022 to 98.7% in 2024, on $6.21B growing to $8.19B. Turkey, the second origin, fell from $108M to $53M over the same window. Origin diversification is not happening in the trade record; if anything, the system is consolidating further toward India.
All molecules, a class, or a portfolio. Default is the full observable export universe; portfolio-scoped runs return the same shape for your specific basket.
Two-year USD growth per origin country. Share of global trade, year-on-year delta, and the implied diversification signal computed at the warehouse layer.
Citation-anchored brief with the gainers, the decliners, and a recommended action for any portfolio molecule whose origin set just narrowed.
India's share is 98.7% of observable trade. The question is whether that share is rising, flat, or falling. The shift number answers it.
An origin set narrowing across multiple portfolio molecules signals concentration deepening. The AI agent flags the molecules and recommends the alternate-origin workflow.
If origin concentration deepens at the country level and lane concentration deepens at the lane level, the entire supply chain is consolidating. Different combinations imply different procurement plays.
Two years dampens single-year tender shocks. The cleaner the time window, the more reliable the directional read.
A real chat thread in PharmaDB. Type a question, the AI agent runs the tools, the answer lands as a saveable note.
pharmagraph_query Twelve pool molecules with at least $5M lane value · share of trade originating in India · 0 to 1 scale · 2024 declared trade.
The origin-shift view is the geographic concentration directional signal. PharmaDB compares two-year origin-country trade shares and surfaces the gainers, decliners, and new entrants. The view is molecule_country_flow; the join is to countries for currency and region context.
The observable global trade data is dominated by Indian trade declarations, and India is the structural majority origin for global API supply. The asymmetry is real, not an artefact. The page exposes the share and its direction across years.
A 10%-plus change in share over two years for an origin contributing more than 1% of global trade. Smaller-origin movers are surfaced separately as new entrants or exits.
If origin concentration deepens at the country level on a lane that is already concentrated, the dual-source workflow upgrades from optional to urgent. The AI agent raises the priority automatically when both signals align.
Yes. Same methodology applies to FDF and intermediates. The shape of the result is the same; the absolute USD levels are different because FDF trade is differently structured.
Trade aggregates refresh monthly. Origin shifts recompute on every refresh. The catalog row carries the last-computed timestamp surfaced on every result page.
Yes. Pass a molecule name and the AI agent returns the origin set just for that molecule. Apixaban is the page's hero example because it sits at 100% India-origin across every observable destination in 2024.
Bring the molecule, the lane, or the supplier you're sourcing this week. The AI agent runs it on PharmaDB in 30 minutes. You keep the brief.